Hereditary diffuse gastric cancer: updated clinical practice guidelines

Authors and Affiliations:

Vanessa RBlairFRACS^ab MaybelleMcLeod^c ProfFátimaCarneiroMD^d ProfDaniel GCoitMD^e Johanna LD'AddarioMHS^f Jolanda Mvan DierenMD^gKirsty LHarrisBPharm^h ProfNicolineHoogerbruggeMDⁱProfCarlaOliveiraPhD^d Rachel Svan der PostMD^j JulieArnold^l Patrick RBenusiglioMD^o Tanya MBisselingMD^k ProfAlexBoussioutasMBBS^p AnnemiekeCatsMD^g AmandaCharltonMBChB^m Karen E ChelcunSchreiber^f Jeremy LDavisMD^q Massimiliano diPietroMD^r ProfRebecca CFitzgeraldMD^r ProfJames MFordMD^tKimberleyGametⁿ IreneGulloMD^d Richard HHardwickFRCS^uProfDavid GHuntsmanMD^v PardeepKaurahPhD^wx Sonia SKupferMD^y AndrewLatchfordMDz^aa ProfPaul FMansfieldMD^ab TakeshiNakajimaMD^acSusanParryMBChB^lJeremyRossaakFRACS^adProfHaruhikoSugimuraMD^af ProfMagaliSvrcekMD^ag MarcTischkowitzMD^s ToshikazuUshijimaMD^ah HidetakaYamadaPhD^af ProfHan-KwangYang^ai AdrianClaydonMBChB^ae JoanaFigueiredoPhD^d KarynParingataiPhD^aj ProfRaquelSerucaPhD^d NicolaBougen-ZhukovPhD^ak TomBrewMSc^ak SimoneBusija^am PatriciaCarneiroPhD^d LynnDeGregorioMBA^an HelenFisherDipEd^h ErinGardner^c Tanis DGodwinMSc^ak Katharine NHolmBS^ao BostjanHumarPhD^ap Caroline JLintottPhD^aq Elizabeth CMonroeMS^an Mark DMullerMBChB^ar EnriqueNoreroMD^as YasminNouriMSc^ak JoanaParedesPhD^d João MSanchesPhD^at EmilySchulpenBSc [Hons]^ak Ana SRibeiroPhD^d AndrewSporleMA^al JamesWhitworthPhD^s LiyingZhangMD^au ProfAnthony EReevePhD^ak ProfParryGuilfordPhD^ak

a Department of Surgery, University of Auckland, Auckland, New Zealand

b St Marks Breast Centre, Auckland, New Zealand

c Kimihauora Health and Research Clinic, Mt Maunganui, New Zealand

d Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal

e Memorial Sloan Kettering Cancer Center and Weill Cornell Medical School, New York, NY, USA

f HereditaryDiffuseGastricCancer.org, Madison, WI, USA

g Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands

h Brisbane, QLD, Australia

i Department of Human Genetics, Radboud University Medical Centre, Nijmegen, Netherlands

j Department of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands

k Department of Gastroenterology, Radboud University Medical Centre, Nijmegen, Netherlands

l New Zealand Familial Gastrointestinal Cancer Service, Auckland Hospital, Auckland, New Zealand

m Department of Histopathology, Auckland Hospital, Auckland, New Zealand

n Genetic Health Service New Zealand Northern Hub, Auckland Hospital, Auckland, New Zealand

o Consultation d'Oncogénétique, Unité Fonctionnelle d'Oncogénétique, Département de Génétique, DMU BioGeM, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, Paris, France

p Department of Medicine, Royal Melbourne Hospital and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia

q Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

r Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK

s Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK

t Division of Oncology, Departments of Medicine and Genetics, Stanford University School of Medicine, Stanford, CA, USA

u Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK

v Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

w Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada

x Hereditary Cancer Program, British Columbia Cancer, Vancouver, BC, Canada

y Section of Gastroenterology, Nutrition and Hepatology, University of Chicago, Chicago, IL, USA

z St Mark's Hospital, London, UK

aa Department of Cancer and Surgery, Imperial College, London, UK

ab University of Texas MD Anderson Cancer Center, Houston, TX, USA

ac Department of Clinical Genetic Oncology, Cancer Institute Hospital, Tokyo, Japan

ad Department of Surgery, Tauranga Hospital, Tauranga, New Zealand

ae Department of Gastroenterology, Tauranga Hospital, Tauranga, New Zealand

af Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan

ag Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Department of Pathology, Hôpital Saint-Antoine, Paris, France

ah Division of Epigenomics, National Cancer Centre Research Institute, Tokyo, Japan

ai Seoul National University Hospital, Seoul, South Korea

aj Te Tumu School of Māori, Pacific and Indigenous Studies, University of Otago, Dunedin, New Zealand

ak Cancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand

al Healthier Lives National Science Challenge, University of Otago, Dunedin, New Zealand

am No Stomach for Cancer, Madison, WI, USA

an DeGregorio Family Foundation, New York, NY, USA

ao Department of Biochemistry and Molecular Medicine, University of California Davis School Of Medicine, Davis, CA, USA

ap Laboratory of the Swiss Hepato-Pancreato-Biliary and Transplantation Centre, Department of Surgery, University Hospital Zürich, Zurich, Switzerland

aq Genetic Health Service New Zealand South Island Hub, Christchurch Hospital, Christchurch, New Zealand

ar Mt Maunganui, New Zealand

as Esophagogastric Surgery Unit, Digestive Surgery Department, Hospital Dr Sotero del Rio, Pontificia Universidad Catolica de Chile, Santiago, Chile

at Institute for Systems and Robotics, Instituto Superior Técnico, Lisbon, Portugal

au Department of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA

Abstract:

Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that is characterised by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is largely caused by inactivating germline mutations in the tumour suppressor gene CDH1, although pathogenic variants in CTNNA1 occur in a minority of families with HDGC. In this Policy Review, we present updated clinical practice guidelines for HDGC from the International Gastric Cancer Linkage Consortium (IGCLC), which recognise the emerging evidence of variability in gastric cancer risk between families with HDGC, the growing capability of endoscopic and histological surveillance in HDGC, and increased experience of managing long-term sequelae of total gastrectomy in young patients. To redress the balance between the accessibility, cost, and acceptance of genetic testing and the increased identification of pathogenic variant carriers, the HDGC genetic testing criteria have been relaxed, mainly through less restrictive age limits. Prophylactic total gastrectomy remains the recommended option for gastric cancer risk management in pathogenic CDH1 variant carriers. However, there is increasing confidence from the IGCLC that endoscopic surveillance in expert centres can be safely offered to patients who wish to postpone surgery, or to those whose risk of developing gastric cancer is not well defined.

Journal: The Lancet Oncology

Link: https://www.sciencedirect.com/science/article/pii/S1470204520302199?dgcid=author